Colorectal tumor molecular phenotype and miRNA: Expression profiles and prognosis

Modern Pathology

Volumn 29, Issue 8, 2016, Pages 915-927

  Slattery, Martha L ^a   Herrick, Jennifer S ^a   Mullany, Lila E ^a   Wolff, Erica ^a   Hoffman, Michael D ^a   Pellatt, Daniel F ^a   Stevens, John R ^b   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ESTROGEN; K RAS PROTEIN; MICRORNA; MICRORNA 192 3P; MICRORNA 196B 5P; MICRORNA 31 5P; MICRORNA 636; MICRORNA 99B 5P; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; COLORECTAL CANCER; CPG ISLAND; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MIDDLE AGED; MOLECULAR DYNAMICS; PHENOTYPE; PRIORITY JOURNAL; RNA ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; AGED; BIOLOGY; CALIFORNIA; CASE CONTROL STUDY; COLORECTAL TUMOR; COMPARATIVE STUDY; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; UTAH;

ADULT; AGED; BIOMARKERS, TUMOR; CALIFORNIA; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; UTAH;

EID: 84969625982     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.73     Document Type: Article

References (62)

1. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
2. Murray BS, Choe SE, Woods M, et al. An in silico analysis of microRNAs: mining the miRNAome. Mol Biosyst 2010; 6: 1853-1862.
3. Arora S, Rana R, Chhabra A, et al. miRNA-Transcription factor interactions: a combinatorial regulation of gene expression. Mol Genet Genomics 2013; 288: 77-87.
4. Gartel AL, Kandel ES. miRNAs: little known mediators of oncogenesis. Semin Cancer Biol 2008; 18: 103-110.
5. Nam S, Li M, Choi K, et al. MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res 2009; 37: W356-W362.
6. Drusco A, Nuovo GJ, Zanesi N, et al. MicroRNA profiles discriminate among colon cancer metastasis. PLoS One 2014; 9: e96670.
7. Acunzo M, Romano G, Wernicke D, et al. MicroRNA and cancer-A brief overview. Adv Biol Regul 2015; 57: 1-9.
8. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856.
9. Slattery ML, Herrick JS, Pellatt DF, et al. MicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa: variations in miRNA expression and disease progression. Carcinogenesis 2016; 37: 245-261.
10. Slattery ML, Wolff E, Hoffman MD, et al. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 2011; 50: 196-206.
11. Valeri N, Vannini I, Fanini F, et al. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 2009; 20: 573-580.
12. El-Murr N, Abidi Z, Wanherdrick K, et al. MiRNA genes constitute new targets for microsatellite instability in colorectal cancer. PLoS One 2012; 7: e31862.
13. Krell J, Stebbing J, Frampton AE, et al. The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network. Lancet 2015; 385 (Suppl 1): S15.
14. Nosho K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014; 35: 776-783.
15. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069.
16. Samowitz WS, Curtin K, Wolff RK, et al. Microsatellite instability and survival in rectal cancer. Cancer Causes Control 2009; 20: 1763-1768.
17. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917-923.
18. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-845.
19. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-beyond physical activity. Cancer Res 1997; 57: 75-80.
20. Slattery ML, Caan BJ, Benson J, et al. Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr Cancer 2003; 46: 166-171.
21. Slattery ML, Edwards SL, Palmer L, et al. Use of archival tissue in epidemiologic studies: collection procedures and assessment of potential sources of bias. Mutat Res 2000; 432: 7-14.
22. Pellatt DF, Stevens JR, Wolff RK, et al. Expression profiles of miRNA subsets distinguish human colorectal carcinoma and normal colonic mucosa. Clin Transl Gastroenterol 2016; 17: e152.
23. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92: 1831-1836.
24. Hinoue T, Weisenberger DJ, Lange CP, et al. Genomescale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-282.
25. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large populationbased sample. J Mol Diagn 2007; 9: 305-314.
26. Agilent Technologies I. Agilent GeneSpring User Manual, Vol. 2015. Aglient Technologies: Santa Clara, CA, 2013.
27. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
28. Benjamini YH, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289-300.
29. Therneau T, A Package for Survival Analysis in S- vol. Version 2.38, 2015; http: /CRAN.R-project.org/package- survival
30. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000.
31. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967; 62: 626-633.
32. Chou CH, Chang NW, Shrestha S, et al. miRTarBase 2016: updates to the experimentally validated miRNAtarget interactions database. Nucleic Acids Res 2015; 44: D239-D247.
33. Kramer A, Green J, Pollard J Jr, et al. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 2014; 30: 523-530.
34. Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-Associated colorectal cancer. Hum Mutat 2012; 33: 551-560.
35. Kim NH, Kim HS, Kim NG, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011; 4ra71.
36. Siemens H, Jackstadt R, Kaller M, et al. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 2013; 4: 1399-1415.
37. Ma Q, Wang X, Li Z, et al. microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep 2013; 29: 1652-1658.
38. Nakazawa K, Dashzeveg N, Yoshida K. Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2 in the apoptotic response to DNA damage. FEBS J 2014; 281: 2937-2944.
39. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25: 1674-1680.
40. Wang G, Cao X, Lai S, et al. Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer. Oncogene 2015; 34: 912-921.
41. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9: 287-314.
42. Amankwatia EB, Chakravarty P, Carey FA, et al. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer 2015; 112: 1480-1490.
43. Cha DJ, Franklin JL, Dou Y, et al. KRAS-dependent sorting of miRNA to exosomes. Elife 2015; 4: e07197.
44. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-1392.
45. Fei BY, Wang XY, Fang XD. MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-Type, KRAS to paclitaxel treatment. Tumour Biol; e-pub ahead of print 18 November 2015.
46. Hara T, Jones MF, Subramanian M, et al. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. Oncotarget 2014; 5: 7635-7650.
47. Hiraki M, Nishimura J, Takahashi H, et al. Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer. Mol Ther Nucleic Acids 2015; 4: e231.
48. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 2013; 32: 2576-2585.
49. Luu C, Heinrich EL, Duldulao M, et al. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. PLoS One 2013; 8: e70604.
50. Ota T, Doi K, Fujimoto T, et al. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 2012; 32: 2271-2275.
51. Ruzzo A, Graziano F, Vincenzi B, et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012; 17: 823-829.
52. Tsunoda T, Takashima Y, Yoshida Y, et al. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res 2011; 31: 2453-2459.
53. Ito M, Mitsuhashi K, Igarashi H, et al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int J Cancer 2014; 135: 2507-2515.
54. Wang Z, Ma B, Ji X, et al. MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. Cancer Cell Int 2015; 15: 40.
55. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007; 6: 54.
56. Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010; 12: 433-440.
57. Mei Q, Xue G, Li X, et al. Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. J Pathol 2015; 236: 165-174.
58. Svrcek M, El-Murr N, Wanherdrick K, et al. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. Carcinogenesis 2013; 34: 828-834.
59. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010; 107: 6982-6987.
60. Yamamoto H, Adachi Y, Taniguchi H, et al. Interrelationship between microsatellite instability and micro-RNA in gastrointestinal cancer. World J Gastroenterol 2012; 18: 2745-2755.
61. Slaby O, Svoboda M, Michalek J, et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
62. Slattery ML, Herrick JS, Mullany LE, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer 2015; 137: 428-438.